As we enter an era of precision cancer medicine, where many drugs are active in small molecularly defined subgroups of patients (e.g., only 3%–7% of lung cancer patients harbor the drug sensitizing EML4-ALK gene fusion [Soda et al., 2007]), the scarcity of models for many cancer genotypes and tissues is a limitation. Here, ALK is linked to lung carcinoma.